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ABSTRACT 
In May 2018, the 121st German Medical Association in Erfurt decided to relax the prohi-
bition of exclusive remote treatment which had previously been standardized in the Model 
Professional Code of Conduct for physicians working in Germany (MBO-Ä). With this, 
the German Medical Association has responded to the continuing call for progress and 
further development in terms of digitization. Nevertheless, many questions remain unan-
swered, such as the implementation and interpretation of the provisions of § 7 para. 4 
MBO-Ä in its new wording and their embedding in existing regulations. Data protection, 
which defines the legal limits of remote treatment, also plays an important role here.
	
		
1  This paper will be published in parallel in German language under the title Digitalisierung in der Medizin im 
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I. INTRODUCTION 
 
Digitization in the health sector has been a perennial issue in legal and medical expert dis-
cussions for several years now. The respective legislative progress can be considered rather 
sluggish, not least because of the controversial picture of opinions. Despite the high num-
ber of supporters in favor of digitization in health care, the amount of critics and skeptics 
is decreasing slowly. 
 
The supporters of remote treatment see an advantage for improving health care, especially 
regarding the demographic changes and the shortage of physicians, not only in rural areas. 
Moreover, due to the possibility of offering short-term consultations, improvements in 
quality of medical services are predicted. Not only the fully employed patient appreciates 
remote treatment as a huge timesaver. Besides, the risk of infection in the physician’s of-
fice can be reduced. Critics of (exclusive) remote treatment fear that the trustful relation 
between patient and physician might suffer from the lack of personal contact. An increase 
of diagnostic errors is predicted due to a restriction in the possibilities of perception and 
cognition. Last but not least, the “new” digital methods of data transfer imply a higher 
risk for the highly sensitive patient health data2. 
 
The physicians’ professional code in Germany reflected these concerns and the require-
ments for patient safety in its former version, valid until the decision of the 121st German 
Medical Association in May 2018. In contrast, neighboring countries such as Switzerland 
have already permitted exclusive remote treatment – without being swamped with re-
proaches of medical malpractice. Foreign providers of remote treatment have already es-
tablished themselves on the German market by requisitioning German physicians3. This 
shows that a “head-in-the-sand-policy” can have counterproductive effects on digitiza-
tion. The decision of the German Medical Association in May 2018 on opening the ban 
of exclusive remote treatment is therefore to be welcomed. 
 
Needless to say that despite all the euphoria about digital progress and digital freedoms, 
the patient health data concerned, which are particularly sensitive in relation to funda-
mental rights, should not be neglected. However – and this aspect is often overlooked – 
data protection requirements are applicable not only for remote treatment, but also in 
every “conventional” physician’s office. Regarding the possibility of fast transfer of large 
datasets and the resulting increased risk potential4, data protection becomes more virulent 
	
		
2  For advantages and disadvantages cf. Peter Kalb, Rechtliche Aspekte der Telemedizin (Legal aspects of telemed-
icine), 8, GESR, 481, 483 (2018). 
3  Cf. speech of the president of the German Medical Association and the German Physicians’ Board, Prof. Dr. 
Frank Ulrich Montgomery, Opening of the 121st German Physicians’ Board in the Steigerwaldstadion Erfurt 
on the 8th of May 2018, 9, https://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/pdf-
Ordner/121.DAET/Eroeffnungsrede_Prof._Montgomery.pdf (last visited Sept. 28, 2018). 
4  Already: Wilfried Berg, Telemedizin und Datenschutz (Telemedicine and data protection), 8, MEDR, 411, 413 
(2004) with further references. 
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in the context of telemedicine. 
II. LEGAL POSSIBILITIES OF REMOTE TREATMENTS IN GERMANY 
 
The revised version of § 7 para. 4 sentence 3 MBO-Ä now reads as follows: “Exclusive 
consultation or treatment via communication media is permitted in individual cases if 
this is medically justifiable and the necessary medical care is maintained, in particular 
through the way in which findings are made, consultation, treatment and documentation 
are provided, and the patient is also informed about the special features of exclusive con-
sultation and treatment via communication media.”. In the future, patients should be 
provided with medical care that corresponds to the recognized state of medical 
knowledge, which includes the further development of telemedicine, digital, diagnostic 
and other comparable possibilities, without establishing a model of primary telemedicinal 
treatment. The personal doctor-patient contact should thus continue to be regarded as 
the “gold standard” of medical treatment5. But what does the change of the MBO-Ä mean 
for physicians? How is the new regulation to be interpreted? And: How does it fit in with 
other legal systems in force? 
 
A. Physicians’ Professional Law 
 
The reformulation of the MBO-Ä alone does not change anything for the attending phy-
sician. The MBO-Ä itself has no legal norm quality and therefore needs to be transposed 
into the professional regulations of the Federal States’ Chambers of Physicians. Although 
the MBO-Ä is not legally binding, it nevertheless serves as a guidance for the Federal 
States’ Chambers of Physicians, so that the earlier prohibition of exclusive remote treat-
ment (old § 7 para. 4 MBO-Ä) has also been adopted analogously by all Federal States’ 
Chambers of Physicians in their professional regulations. Today, however, this no longer 
applies without restrictions. In summer 2016, the State Chamber of Physicians in Baden-
Württemberg has already changed its professional regulations and approved remote treat-
ment of Baden-Württemberg patients by Baden-Württemberg physicians for model pro-
jects. This year, the Federal States’ Chambers of Physicians of Schleswig-Holstein and Sax-
ony have also legitimized the exclusive remote treatment in cases of medical justifiability 
by amending the respective Professional Code of Conduct.  
Finally, the representatives’ meeting of the Rhineland-Palatinate State Chamber of Phy-
sicians – very recently – decided on 20th September 2018 on a corresponding new regula-
tion of the Professional Code of Conduct. 
 
It can be assumed that other regional Chambers of Physicians will amend their profes-
sional regulations in accordance with the new provisions of § 7 para. 4 MBO-Ä. On the 
	
		
5  Synopsis of the changes in § 7 Abs. 4 MBO-Ä (remote treatment), https://www.bundesaerztekam-
mer.de/fileadmin/user_upload/downloads/pdf-Ordner/MBO/Synopse_MBO-AE_zu_AEnder-
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other hand, in May 2018 the Saarland Chamber of Physicians – following the resolution 
of the 121st German Medical Association – expressly spoke out against a relaxation of the 
prohibition of exclusive remote treatment6, with the result that the professional law will 
probably be fragmented in this respect. In the context of remote treatment, the question 
of the applicable professional law will therefore soon arise.  
 
The physician is a compulsory member of the regional Chamber of Physicians in whose 
district he practices his profession. He is therefore also subject to their professional code 
of conduct. In the case of a “normal” visit to the doctor, it is clear that the doctor exercises 
his profession at the office. But does this also apply if the doctor offers online video con-
sultation hours from his practice, during which he treats patients from other chamber 
districts? There is much to be said in favor of continuing to determine the physician’s 
place of business as the place where he exercises his profession7. A different understanding 
would lead, in particular, to considerable practical difficulties. Based on the patient’s ac-
tual whereabouts during treatment – which could alternatively be taken as a basis – the 
attending physician would possibly become a compulsory member of a large number of 
regional chambers of physicians, which in turn could lead to an unreasonable burden on 
the exercise of the physician’s profession. Ultimately, determining the patient’s actual 
whereabouts could also mean unreasonable additional work for the doctor. All this would 
in any case make remote treatment extremely unattractive from a medical point of view, 
so that the desired progress would not be achieved. 
 
B. New wording of § 7 para. 4 of the Model Professional Code of Conduct   
(MBO-Ä) 
 
According to § 7 para. 4 sentence 3 MBO-Ä in its new wording it should definitely be 
decisive in the future whether the attending physician considers the exclusive remote 
treatment to be medically justifiable in the individual case. But when is remote treatment 
medically justifiable? And what defines an individual case? There is no legal definition for 
this. 
It is safe to assume that the previously permitted options of remote treatment will also be 
permitted under the new regulation8. However, the new regulation is expressly intended 
	
		
6  Cf. Andeas Kindel, Fernbehandlung, Saar-Ärzte fürchten Kontrollverlust (Remote treatment, Saar-physicians 
fear loss of control), ÄRZTEZEITUNG ONLINE (May 2 2018), https://www.aerztezeitung.de/politik_gesell-
schaft/berufspolitik/article/963095/fernbehandlung-saar-aerzte-fuerchten-kontrollverlust-telemedizin.html 
(last access Sept. 28, 2018). 
7  The question of the professional law also arises in particular with regard to the cross-border telemedical activ-
ities of physicians who are established in another EU member state. 
8  § 7 para. 4 MBO-Ä (old version) has not standardized a general prohibition of remote treatment measures, 
rather only diagnosis and therapy recommendation for unknown patients via print and communication media 
– i.e. in the context of the first contact – should be completely prohibited by this law, cf. in this regard: Notes 
and explanations of the Federal Chamber of Physicians on § 7 para. 4 MBO-Ä (remote treatment), 11.12.2015 
https://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/pdf-Ordner/Recht/2015-12-
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to permit other forms of remote treatment, in particular the initial contact via means of 
communication.  
 
In order to determine the regulatory content, the view taken here is that the principle of 
freedom of medical treatment recognized by the highest court9 and the case-law on med-
ical liability can be relied upon. Medical freedom of therapy means here that the physician 
can in principle choose the examination and treatment methods – among the permissible 
treatment methods – freely, he thus possesses a discretionary and judgmental scope in this 
respect10. This means that the proper course of medical action is determined exclusively 
by whether the physician has made justifiable decisions about diagnostic and therapeutic 
measures using “the medical knowledge and experience required from him in the specific 
case and has carefully implemented these measures”11. 
 
Correctly, the physician must therefore ask in relation to the intended purpose what 
“form of depth of the physicians’ perception of the patient is necessary for the physician 
for standard treatment”12. The physician must therefore assess the risks of remote treat-
ment on his own responsibility on a case-by-case basis, i.e. in relation to the treatment and 
the patient. As soon as the doctor considers a personal visit of the patient to be indicated, 
he has to point this out to the patient and interrupt the remote treatment. As with any 
other therapy recommendation, it is then up to the patient to actually follow this up. 
 
If the physician decides to carry out remote treatment, even though this was not medically 
justifiable in the individual case, this violation of professional duties can lead to civil lia-
bility.  
The choice of a medically unjustifiable form of therapy can quickly be regarded as a gross 
medical malpractice in a lawsuit. 
 
The physician should also pay special attention to patient information, because in the 
context of remote treatment the physician must also inform about the special features of 
consultation and treatment exclusively via communication media. The obligatory con-
tent of this information is not defined, but can also be determined according to the tradi-
tional principles. However, it is recommended to expressly point out to the patient that 
not all diagnostic possibilities, such as palpating, can be used in the context of remote 
treatment – even if this is likely to be self-explanatory to the patient on a regular basis. 
This recommendation applies at least as long as there is no highest court jurisdiction on 
	
		
Kuhn, Grenzen der Digitalisierung der Medizin de lege lata und de lege ferenda (Limits to digitization in 
health care de lege lata and de lege ferenda), 12, GESR, 748 (2016). 
9  Cf. BGH (German Federal Supreme Court), decision dated Sept. 22, 1987 – VI ZR 238/86, NJW 1988, 763, 
764. 
10  LAUFS/KERN, HANDBUCH DES ARZTRECHTS (MANUAL OF MEDICAL LAW), § 97 Rn. 36, (4th ed. 2010). 
11  BGH (German Federal Supreme Court), decision dated March 10, 1987 – VI ZR 88/86, NJW 1987, 2291, 2292. 
12  Michael Hahn, Telemedizin und Fernbehandlungsverbot – Eine Bestandsaufnahme zur aktuellen Entwicklung 
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this, because in a medical liability lawsuit the physician has to prove the correctness of the 
information. The special information and consent should also be included in the patient 
documentation. 
 
C. Federal regulations 
 
The amendment of the MBO-Ä or the professional law alone is not sufficient to reason-
ably integrate remote treatment into the system of medical care. Rather, an extensive ac-
tion by the legislator is required here. Some statutory provisions currently stand in the 
way of an effective offer of remote treatment services – this is illustrated by the example 
of the provisions of § 9 of the German Act on Advertising of Medicinal Products (HWG) 
and § 48 of the German Medicinal Products Act (AMG). 
 
1. § 9 German Act on Advertising of Medicinal Products (HWG) 
 
According to § 9 HWG, advertising for the recognition or treatment of diseases, suffer-
ings, bodily injuries or pathological complaints that are not based on the physician’s own 
perception of the patient is not permitted. Although it is not the remote treatment itself 
that is prohibited, but only the advertising for the same, the provision under the law on 
therapeutic product advertising nevertheless stands in the way of an appropriate offer of 
remote treatment services. There is no distinction according to whether distance treat-
ment is permissible or inadmissible under professional law, so that the wording of the 
provision is clear. It is well known that the wording represents the limit of any interpre-
tation. Any interpretation to the effect that forms of remote treatment permitted under 
professional law are not covered by the advertising ban cannot be made for this and other 
reasons13. The medical professional codes of conduct are established as statutory law in 
the hierarchy of norms below formal statutory law. The result of an interpretation cannot 
be that the formal-legal prohibition norm of § 9 HWG is leveraged by sublegal statute 
right. In addition, this type of interpretation would (probably) lead to the fact that federal 
law would have to be interpreted inconsistently in the individual chamber districts, since 
- as previously described - not all regional medical associations have adopted or will adopt 
the opening clause adopted in the MBO-Ä in their professional regulations. 
 
According to the opinion represented here, it is questionable whether the "mere" offering 
of remote treatment services on a doctor's homepage is already to be regarded as advertis-
ing in the sense of the provision14. However, this is possible in individual cases, depending 
	
		
13  Different view: Julia Braun, Die Zulässigkeit von ärztlichen Fernbehandlungsleistungen nach der Änderung 
des § 7 Abs. 4 MBO-Ä (The admissibility of remote treatment services after the change of § 7 para. 4 MBO-
Ä), 36, MEDR, 563, 566 (2018); Michael Hahn, Telemedizin und Fernbehandlungsverbot – Eine Bestandsauf-
nahme zur aktuellen Entwicklung (Telemedicine and ban of remote treatment – an inventory of the latest 
developments), 36, MEDR, 384, 386 (2018). 
14  According to the Ministry for Social Affairs and Integration of the State of Baden-Württemberg, remote treat-
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on the form it takes, due to the broad advertising concept of the law on the advertising of 
therapeutic products 15. Enabling the provision of exclusive remote treatment services 
without mentioning this on the homepage, on the other hand, would be a waste of time. 
Even if the legal literature rightly raises the question of whether "own perception" within 
the meaning of § 9 HWG requires an offline contact purely conceptually16, this will not 
lead to a legally secure solution for the physician. In any case, it has already been decided 
in the case law of higher courts that remote treatment within the meaning of § 9 HWG is 
to be present if the treating person makes a diagnosis or submits treatment proposals 
solely on the basis of written information, information provided by telephone, other me-
dia or third parties at a distance17. Undoubtedly, the online video consultation should also 
be subsumed under this heading. Legislative action is therefore absolutely necessary, not 
least because a violation of § 9 HWG under § 15 para. 1 No. 6 HWG constitutes an admin-
istrative offence, which can be punished with a fine of up to € 50,000.00 (§ 15 para. 3 
HWG). 
 
2. § 48 German Medicines Act (AMG) 
 
Pursuant to § 48 para. 1 sentence 1 AMG, medicinal products intended for human use 
may not be supplied if there has obviously been no direct contact between the doctor and 
the person to whom the medicinal product is prescribed prior to medical treatment18. Ac-
cording to § 48 para. 1 sentence 3 AMG, exceptions may be made in justified exceptional 
cases, in particular if the patient and doctor know each other from a previous direct con-
tact or if the treatment is merely repeated or continued. This provision therefore at least 
opens up the possibility of interpretation to the effect that in the case of remote treatment 
permitted under professional law, there is a justified exception within the meaning of the 
provision. However, this conclusion is by no means mandatory, so that § 48 AMG also 




W printed matter 16/3161 p. 3. This interpretation is, however, at least questionable, since such restriction is 
not included in the wording of § 9 HWG. 
15  Cf. on this topic: Julia Braun, Die Zulässigkeit von ärztlichen Fernbehandlungsleistungen nach der Änderung 
des § 7 Abs. 4 MBO-Ä (The admissibility of remote treatment services after the change of § 7 para. 4 MBO-
Ä), 36, MEDR, 563, 566 (2018). 
16  Cf. Michael Hahn, Telemedizin und Fernbehandlungsverbot – Eine Bestandsaufnahme zur aktuellen Entwick-
lung (Telemedicine and ban of remote treatment – an inventory of the latest developments), 36, MEDR, 384, 386 
(2018). 
17  OLG (Higher Regional Court) Munich, decision dated Aug. 2, 2012 – 29 U 1471/12, MMR 2012, 824. 
18  On the concerns about this provision under European law see Ulrich M. Gassner, Verbot von Online-
Verschreibungen von Medikamenten: Patientenautonomie unter Dauerfeuer (Ban of online-prescriptions of 
medicines: patient autonomy under constant fire), LEGAL TRIBUNE ONLINE, March 31, 2016, 
https://www.lto.de/recht/hintergruende/h/arzneimittel-recht-online-rezept-kontakt-arzt-patient-gesetz-
entwurf-bevormundung/ (last visited Sept. 28, 2018). 
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III. LEGAL LIMITS TO DIGITIZATION: DATA PROTECTION IN THE HEALTH 
SECTOR 
 
The new provisions of data protection law must also be taken into account when assessing 
permissible remote treatment and its limits. Due to the "new" technical possibilities of the 
rapid exchange of large amounts of data, measures must be taken in the interest of the 
persons concerned and the principle of data economy to take account of this change. In 
this respect, the new regulations at least contribute to raising awareness, despite all the 
displeasure. What, then, must doctors pay particular attention to when offering remote 
treatment services relating to data protection? 
 
A. GDPR and BDSG-new 
 
The regulation (EU) 2016/679 on the protection of natural persons with regard to the 
processing of personal data and on the free movement of such data and on the repeal of 
Directive 95/46/EC (General Data Protection Regulation, hereinafter referred to as 
"GDPR") entered into force on May24, 2016. In many places, however, it was only per-
ceived shortly before or with its immediate commencement of application in all EU mem-
ber states on May 25, 2018. It is intended to lead to a uniform application of the law and 
to give affected persons more control and transparency, especially in the digital age. The 
innovations go hand in hand with a tightening of the burden of proof on the part of those 
responsible for data processing. The GDPR addresses not only corporations such as 
Google, Facebook and Co., which were the primary target of the legislators in the reform, 
but also small companies, including physicians’ offices, pharmacies and even privately run 
associations. The GDPR does not provide for the possibility of a general exemption for 
smaller units, but it does contain some exceptions, for example with regard to the require-
ment to appoint a data protection officer. 
 
In addition to the introduction of the GDPR, which applies directly in all member states 
and does not require transposition into national law, the Federal Data Protection Act has 
also been amended in Germany and also entered into force on May 25, 2018 (BDSG-neu) 
by adapting some points to the European framework and filling in the reserved opening 
clauses. The criminal provisions are also reserved for the BDSG-new due to the lack of 
regulatory competence of the EU and can be found there in §§ 41 to 43 BDSG-new. 
 
In terms of content, the principles of secure handling of personal data are not entirely 
new. Particularly with regard to sensitive data such as health data, the old BDSG, which 
implemented Directive 95/46/EC, already had high requirements. The increased require-
ments for information and proof obligations can therefore be implemented well by an 
appropriate internal data protection concept. Nevertheless, there are uncertainties in the 
interpretation of the Regulation with regard to individual special questions, which will 
be explained below and which will have to be answered in the near future by binding 
specifications of the European Data Protection Committee, the national data protection 
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B. Notions and definitions 
 
First, the question arises as for which information the GDPR is applicable at all. Accord-
ing to Art. 4 No. 1 GDPR, personal data are "any information relating to an identified or 
identifiable natural person ("data subject"); an identifiable natural person is one who can 
be identified directly or indirectly, in particular by reference to an identifier such as a 
name, an identification number, location data, an online identifier or to one or more spe-
cific characteristics which express the physical, physiological, genetic, psychological, eco-
nomic, cultural or social identity of that natural person". This includes in particular in-
formation such as first name and surname, address, telephone number, e-mail address and 
date of birth, which are collected as standard in the medical practice. This is referred to as 
simple personal data. 
 
1. Health data 
 
Particularly sensitive data such as health data are subject to special protection under the 
GDPR. Health data are defined in Art. 4 No. 15 GDPR as such "personal data related to 
the physical or mental health of a natural person, including the provision of health care 
services, which reveal information about his or her health status". According to recital 35 
of the GDPR19, this includes in particular information on past, present or future physical 
and mental health. The information is already personally identifiable if numbers, symbols 
or identifiers assigned to a natural person are used to uniquely identify that natural person 
for health purposes. 
Examples of health data can therefore already be the insurance number, pre-existing con-
ditions, diagnoses (indications), as well as all laboratory results, blood and tissue samples, 
but also disease risks attributable to a natural person. 
 
2. Anonymization and pseudonymization 
 
It should therefore be noted that - in accordance with recital 26 of the GDPR - pseudon-
ymized data also clearly fall within the scope of the GDPR. This also applies if the person 
who receives and processes the pseudonymized data cannot draw conclusions about the 
natural person without consulting further information. Pseudonymization is defined in 
Art. 4 No. 5 GDPR as "the processing of personal data in such manner that it can no 
longer be attributed to a specific person without the use of additional information, pro-
vided that such additional information is kept separately and is subject to technical and 
organizational measures to ensure that the personal data are not attributed to an identi-
fied or identifiable natural person". A classic example is the assignment of an identifica-
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Only for anonymous data the GDPR does not apply. However, the terms "anonymous" 
or "anonymization" are not defined. In general, anonymization is presumed when it is no 
longer possible to assign a person to a specific or identifiable natural person20. In this case, 
the allocation key for tracing the identification number back to the corresponding person 
must no longer exist. 
 
The distinction between anonymization and pseudonymization plays an important role 
in the context of remote treatment, especially with regard to the transmission of data. In 
view of the new definition, the transfer of data to medical specialists can no longer be seen 
as anonymization, as it will always be possible to identify the person. In addition, the dif-
ferentiation can become relevant when cooperating with pharmaceutical companies, e.g. 
when creating databases, registers or observational studies. Here, too, anonymization is 
only possible if neither the physician nor the pharmaceutical company can identify the 
individual patient. 
 
It should also be emphasized that any operation relating to personal data constitutes pro-
cessing within the meaning of Art. 4 No. 2 GDPR; even the collection, but also the mere 
deletion, is regarded as processing and no distinction is made between individual pro-
cessing operations. 
 
C. Legal bases for data processing 
 
Furthermore, the fundamental prohibition of data processing without a legal basis, the 
so-called prohibition subject to permission, continues to apply. Corresponding legal bases 
can be found in Art. 6 para. 1 lit. a) to f) GDPR for "simple" personal data, in Art. 9 para. 
2 lit. a) to j) GDPR for special categories of personal data, in particular health data, as well 
as in § 22 BDSG-new. Permission may be granted either by legal basis or by the express 
consent of the data subject. 
 
Although consent is better suited as evidence, the use of a legal basis is likely to be more 
valuable overall - if a legal basis can be substantiated accordingly - as the consent can be 
revoked by the data subject at any time. 
 
To determine the respective legal basis, each processing operation and the purpose of the 
data processing must be considered individually. 
 
1. Medical treatment and health care as a legal basis 
 
Generally, the collection of data by the physician should take place on the basis of the 
treatment contract and thus be permitted in accordance with Art. 9 para. 2 lit. h) GDPR 
in conjunction with § 22 para. 1 b) BDSG-new. A declaration of consent by the patient is 
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therefore not usually necessary for "normal" treatment. However, due to the principle of 
purpose and data minimization (Art. 5 para. 1 lit. b) and c) GDPR), this only applies to 
the extent that data processing is necessary for the purpose, i.e. for carrying out the treat-
ment, so that the scope of processing is limited to the extent necessary for this purpose21. 
 
But what is the necessary measure for a treatment via electronic communication media - 
e.g. the online video consultation? Is the assessment of necessity to be based on the per-
formance of medical treatment in general, or on the specific form of treatment? 
 
Referring to the treatment contract as a whole, it can be assumed that it is not necessary 
to use additional software to carry out the online video consultation, as the treatment 
contract can also be fulfilled in another way, namely by personal examination in the phy-
sician’s office. The transmission of data by video goes beyond what is necessary, so that 
for the purposes of remote treatment a data protection consent would have to be ob-
tained. Focusing, on the other hand, on the special form of treatment, i.e. remote treat-
ment as such, one would come to the conclusion that no separate consent under data pro-
tection law has to be obtained, because the video consultation hour with the use of addi-
tional communication media is necessary to fulfil the treatment contract in its special 
form. 
 
Also § 7 para. 4 MBO-Ä (new version) does not provide an answer to these questions, but 
only demands in medical regard that "the patient is also informed about the peculiarities 
of the exclusive consultation and treatment via communication media". An additional 
data protection clarification and informed consent is not expressly prescribed in any case 
- unlike, for example, § 40 para. 2a AMG for participation in the clinical trial. 
 
In the direct contact between doctor and patient, the special type of data processing 
should be regarded as necessary according to the view held here. Finally the change of the 
MBO-Ä opens the clearance of the exclusive remote treatment for the physician in the 
context of its therapy choice and under consideration of the medical care to the physician. 
In the same way, within the framework of traditional treatment, he is free to decide on 
the manner and means of treatment in compliance with medical standards. Depending 
on which type of treatment he chooses, the appropriate implementation is necessary for 
the fulfilment of the specific treatment contract, so that no additional data protection 
consent is required in the context of remote treatment. 
 
2. Informed consent for processing of patient health data 
 
However, a direct transfer of personal health data, for example in order to obtain a 
(tele)consultation or in connection with a referral to a specialist - as in the context of con-
ventional treatment - will only be possible with the consent of the patient, cf. also § 73 
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para. 1b of the German Social Insurance Code (SGB V). It should be emphasized in this 
context that - as described above - pseudonymous data already fall within the scope of the 
GDPR. For this reason, the transmission of an X-ray image or ECG alone - without men-
tioning the patient's name - is already to be regarded as a processing operation22. The pa-
tient's consent must also be obtained for other purposes which go beyond the fulfilment 
of the treatment contract23, e.g. the sending of appointment reminders. Since the transfer 
of data is often part of the treatment, the patient's general consent under data protection 
law will probably have to be obtained in these cases. 
 
D. Further aspects of data protection 
 
1. Rights of the data subject 
 
It is important to note that, independent of the legal basis that permits the processing of 
personal data and health data, the data subject must always be informed in accordance 
with Art. 13 GDPR about the data collection in its concrete form - irrespective of whether 
the patient's consent under data protection law is obtained or not. Depending on the 
technical design, problems may arise with regard to the scope of the information obliga-
tions, for example if other players are involved in addition to the physician (e.g. platform 
operators). At a minimum, the physician must provide information on the identity of the 
person(s) responsible24, the contact details of the data protection officer, the purposes of 
the processing, recipients or categories of recipients, the duration of the processing and 
the rights of the data subjects pursuant to Art. 15 et seq. GDPR to this effect. If the treat-
ment is carried out exclusively via telephone/video telephony, the physician must also in-
form in this way. The reference to a notice in practice would therefore not be sufficient, 
but possibly data protection information on the doctor's website, if he actively refers to it 
during the online video consultation25. An exception to the duty to inform exists accord-
ing to Art. 14 para. 5 lit. d) GDPR if the doctor has received the patient's data from a third 
party (permissibly) and they are subject to professional secrecy. This is the case, for exam-
ple, if the primary care physician forwards the patient data to the specialist because it can 





22  Different according to the former legal status; cf. Wilfried Berg, Telemedizin und Datenschutz (Telemedicine 
and data protection), 8, MEDR, 411, 414 (2004). 
23  Cf. on this topic: Joachim Schütz/Bernd Halbe, Wann die Patienteneinwilligung notwendig ist (When patient 
consent is necessary), ÄRZTEZEITUNG ONLINE (MEDICAL JOURNAL ONLINE), Aug. 24 2018, 
https://www.aerztezeitung.de/praxis_wirtschaft/w_specials/datenschutzverordnung/article/969712/daten-
verarbeitung-wann-patienten-einwilligung-notwendig.html (last visited Sept. 28, 2018). 
24  For joint controlling see below under 4.b. 
25  Also: recommendation of the North Rhine Chamber of Physicians, Die DSGVO in den Praxisalltag integri-
eren (Integrating GDPR into the physician’s routine), RHEINISCHES ÄRZTEBLATT (RHENISH MEDICAL 
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In addition, the requirements of Art. 9 para. 3 GDPR must be fulfilled. Accordingly, pro-
cessing is only permissible if it is carried out "by specialist personnel or under their respon-
sibility" and if this specialist personnel or the person responsible for data processing is 
subject to a statutory professional secret or other confidentiality obligation26. This shall 
include appropriate measures to safeguard the interests of the data subject and data secu-
rity in general27. 
 
Furthermore, it must be ensured that the data subject can exercise his or her right to in-
formation (Art. 15 GDPR) and, if applicable, data portability (Art. 20 GDPR) without 
any problems. The latter means that the patient can request a copy of his patient file. 
However, it only exists if the processing is based on consent or a contract and is carried 
out using automated procedures. In the case of remote treatment, this means that the pa-
tient has no right to data transferability if the data processing is based - as described above 
- on the treatment contract as legal basis, since the legal basis of the health care and the 
treatment contract from Art. 9 para. 2 lit. h) GDPR is not mentioned in the concluding 
enumeration28 of Art. 20 para. 1 a) GDPR29. The right of the patient to inspect the patient 
file according to § 630g of the German Civil Code (BGB) remains unaffected by this. In 
contrast to the right under Art. 20 GDPR, the physician is not given a deadline to react 
and the patient must bear the costs incurred himself. 
 
Even if a third party is involved as platform operator, this should not lead to a different 
result: A contract within the meaning of Art. 6 para. 1 lit. b) GDPR would – if at all – be 
concluded between platform operator and physician - but not between platform operator 
and patient30. Apart from hat, however, only the processing of "simple" personal data by 
the platform operator would be permitted, which would not be sufficient for the desired 
purposes. 
 
2. Joint controlling/Commissioned data processing 
 
Since the GDPR came into force, there have also been new responsibilities for the involve-
ment of several actors in connection with data processing. Art. 4 No. 7 GDPR defines the 
	
		
26  Cf.EHMANN/SELMAYR/SCHIFF, DSGVO KOMMENTAR (GDPR COMMENTARY), Art. 9 Rn. 61 (2nd ed. 2018). 
27  So called technical and organizational measures (TOMs) such as access restrictions, password protection, en-
cryption and ensuring the integrity and availability of systems, etc., cf. Art. 24 para. 1 GDPR, § 22 para. 2 
BDSG-new. 
28  Cf. recital 68; PAAL/PAULY/PAAL, DS-GVO KOMMENTAR (GDPR COMMENTARY), Art. 20 Rn. 18 (2nd ed. 
2018). 
29  In the result also: Andreas Wolf, Die Fernbehandlung nach dem 121. Deutschen Ärztetag im Lichte der 
DSGVO (Remote treatment after the 121st German Medical Association in the light of the GDPR), 4, GUP, 
129 et seq (2018). 
30  Different view: Andreas Wolf, Die Fernbehandlung nach dem 121. Deutschen Ärztetag im Lichte der DSGVO 
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person responsible as the person who alone or jointly with others differentiates between 
the purposes and means of data processing. Accordingly, anyone who collects, stores, 
transmits, etc. data for himself is responsible. Responsible person in the sense of the 
GDPR31. In contrast, the processor is, according to Art. 4 No. 8 GDPR, a person or body 
who processes personal data on behalf of the data controller. The delimitation is im-
portant because the responsible person and the processor have different obligations32 and 
a corresponding agreement must be reached on the distribution of responsibilities in ac-
cordance with Art. 26 or Art. 28 GDPR.  
 
Due to the contractual and professional duties of a physician to document patient data 
and to archive it beyond the treatment33, the physician defines the processing purposes at 
least to this effect and is therefore generally to be regarded as the person responsible. The 
specialist to whom the referral is made by the family doctor also does not act as processor 
on behalf of the primary physician34, since an independent legal relationship is established 
with the patient and he does not act on his behalf35. Cooperation between physicians and 
pharmaceutical companies - not only within the framework of clinical trials36 - will also 
regularly be a joint responsibility, since in some areas decisions are made on data pro-
cessing and corresponding internal regulations are required.  
 
In the context of remote treatment, it is conceivable, depending on the technical imple-
mentation, that the physician may use one or more service providers who, in accordance 
with their dependence on the physician's mandate or their own influence on data pro-
cessing, are to be classified as contract processors or joint responsible parties. 
 
3. Data protection officer 
 
In addition, the appointment of a data protection officer pursuant to Art. 37 GDPR will 
be necessary in practices offering remote treatment. Although the core activity of a medi-
cal practice mentioned in Art. 37 para. 1 lit. c) GDPR is not usually seen as an extensive 
	
		
31  PAAL/PAULY/ERNST, DS-GVO KOMMENTAR (GDPR COMMENTARY), Art. 4 Rn. 55 (2nd ed. 2018). 
32  At the same time, the obligations of commissioned data processors have increased and an independent liability 
has been established. 
33  Cf. § 630 f para. 3 BGB, § 28 RöV (X-Ray Regulation). 
34  According to the statement of the Data Protection Officer of North-Rhine Westphalia, which is no longer 
available, cf. the resolution of the Concerted Action of the Professional Associations at the German National 
Association of Statutory Health Insurance Physicians, June 22, 2018, http://www.kbv.de/html/35530.php (last 
visited Sept. 28, 2018). 
35  Already: BGH (Federal Supreme Court), decision dated Jan. 14, 2010 – III ZR 188/09, NJW 2010, 1200; BGH, 
decision dated Jan. 14, 2010 – III ZR 173/09, NJW 2010, 1203. 
36  Cf. Short paper of the Data Protection Conference on Joint controlling, March 19, 2018, 
https://www.ldi.nrw.de/mainmenu_Aktuelles/submenu_EU-Datenschutzreform/Inhalt/EU-Datenschutz-
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processing of personal data37, it is subject to the duty to assess the impact of data protec-
tion due to the "use of new technologies" pursuant to § 38 para. 1 sentence 2 BDSG-new 
in conjunction with Art. 37 para. 1 GDPR, so that even smaller practices with less than 
ten employees must appoint a data protection officer when offering remote treatment. In 
addition, a list of processing activities in accordance with Art. 30 GDPR must be main-
tained in which the steps to be taken in connection with remote treatment must be listed 
as individual processing steps. 
 
Finally, what are the consequences of the GDPR for breaches of data protection provi-
sions? On the one hand, the framework for the imposition of fines has been drastically 
increased and can now amount to up to EUR 20 million or 4% of the annual turnover in 
the case of serious infringements, for example of consent requirements or the rights of the 
data subject pursuant to Art. 83 para. 5 GDPR. On the other hand, pursuant to Art. 82 
para. 1 GDPR, the data subject has a claim for damages against the data controller and the 
processor if he or she succeeds in proving material or immaterial damage resulting from a 
breach of data protection. 
IV. CONCLUSION 
 
The amendment to § 7 para. 4 MBO-Ä (new version) is a first important step towards 
enabling exclusive remote treatment, which is becoming increasingly important in the 
course of digitization. Fortunately, it has now been recognized that the current attempt 
to close off the German healthcare market from remote treatment cannot be the future. 
The restraint of the medical profession in this regard can only be countered, however, if 
more legal clarity is created regarding the interpretation of the new professional regula-
tions and regarding the possible consequences of the impending fragmentation of profes-
sional law with regard to the prohibition of remote treatment. In addition, legislative ac-
tion is absolutely necessary, as the currently applicable statutory provisions blatantly 
stand in the way of a meaningful offer of distance treatment services. In addition to the 
professional limits, the physician in charge must also take into account the new data pro-
tection regulations, which will entail a number of organizational hurdles. Against the 
background of stricter accountability obligations and monetary liability risks, compliance 




37  Different view: Chamber of Physicians of the State of Hesse, which advises to appoint a data protection officer 
in health care institutions with less than ten employees at least for a transitional period of two years, cf. 
Handout on Appointment of DPO in the view of the Chamber of Physicians of the State of Hesse, 
https://www.laekh.de/images/Aerzte/Neues_Datenschutzrecht/Bestellung_eines_Datenschutzbeauftrag-
ten.pdf (last visited Sept. 29, 2018). 
